The roles of CAR-T product-derived bystander T cells for BsAb therapy (IMAGE)
Caption
A CAR-T cell product can contain both CAR-T cells and CAR-negative bystander T cells (left). After treatment with CAR-T cell therapy, CAR-T cells kill tumor cells and release a panel of cytokines. In the presence of those cytokines, simultaneously transferred product-derived bystander T cells and remaining bystander T cells in the body have an opportunity to expand and form memory T cells (middle). Especially, product-derived bystander CAR-CD8+ T cells can further proliferate after BsAb therapy, resulting in enhanced therapeutic effects against relapsed tumor cells (right).
Credit
Junichi Kato,Tatsuya Konishi,Toshiki Ochi,Katsuto Takenaka,Ehime university
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC